Monaghan D[au] - Search Results

Year	Number of Results
1958	1
1981	2
1982	2
1983	4
1984	3
1985	5
1986	7
1987	2
1988	4
1989	5
1990	5
1991	5
1992	2
1993	1
1994	2
1995	2
1996	1
1997	3
1998	7
1999	1
2000	3
2002	2
2003	1
2004	3
2005	4
2006	5
2007	3
2008	4
2009	6
2010	2
2011	4
2012	7
2013	6
2014	2
2015	5
2016	4
2017	5
2018	5
2019	7
2020	4
2021	5
2022	4

1

Surface properties and the perception of color.

Isherwood ZJ, Huynh-Thu Q, Arnison M, Monaghan D, Toscani M, Perry S, Honson V, Kim J. Isherwood ZJ, et al. Among authors: monaghan d. J Vis. 2021 Feb 3;21(2):7. doi: 10.1167/jov.21.2.7. J Vis. 2021. PMID: 33576764 Free PMC article.

2

Using Sprint Velocity Decrement to Enhance Acute Sprint Performance.

Cochrane DJ, Monaghan D. Cochrane DJ, et al. Among authors: monaghan d. J Strength Cond Res. 2021 Feb 1;35(2):442-448. doi: 10.1519/JSC.0000000000002707. J Strength Cond Res. 2021. PMID: 29927891

3

Pharmacology of NMDA Receptors.

Monaghan DT, Jane DE. Monaghan DT, et al. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 12. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 12. PMID: 21204415 Free Books & Documents. Review.

4

Lectin Affinity Chromatography (LAC).

O'Connor BF, Monaghan D, Cawley J. O'Connor BF, et al. Among authors: monaghan d. Methods Mol Biol. 2017;1485:411-420. doi: 10.1007/978-1-4939-6412-3_23. Methods Mol Biol. 2017. PMID: 27730567

5

The continually evolving role of NMDA receptors in neurobiology and disease.

Collingridge GL, Monaghan DT. Collingridge GL, et al. Among authors: monaghan dt. Neuropharmacology. 2022 Jun 1;210:109042. doi: 10.1016/j.neuropharm.2022.109042. Epub 2022 Mar 17. Neuropharmacology. 2022. PMID: 35307365

6

The NMDA receptor as a target for cognitive enhancement.

Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnár E, Lodge D, Jane DE. Collingridge GL, et al. Among authors: monaghan dt. Neuropharmacology. 2013 Jan;64:13-26. doi: 10.1016/j.neuropharm.2012.06.051. Epub 2012 Jul 11. Neuropharmacology. 2013. PMID: 22796429 Free PMC article. Review.

7

Can Backward Sled Towing Potentiate Sprint Performance?

Monaghan DJ, Cochrane DJ. Monaghan DJ, et al. J Strength Cond Res. 2020 Feb;34(2):345-354. doi: 10.1519/JSC.0000000000003322. J Strength Cond Res. 2020. PMID: 31403574

8

Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Burnell ES, Irvine M, Fang G, Sapkota K, Jane DE, Monaghan DT. Burnell ES, et al. Among authors: monaghan dt. J Med Chem. 2019 Jan 10;62(1):3-23. doi: 10.1021/acs.jmedchem.7b01640. Epub 2018 Mar 5. J Med Chem. 2019. PMID: 29446949 Free PMC article. Review.

9

Structural basis of subtype-selective competitive antagonism for GluN2C/2D-containing NMDA receptors.

Wang JX, Irvine MW, Burnell ES, Sapkota K, Thatcher RJ, Li M, Simorowski N, Volianskis A, Collingridge GL, Monaghan DT, Jane DE, Furukawa H. Wang JX, et al. Among authors: monaghan dt. Nat Commun. 2020 Jan 22;11(1):423. doi: 10.1038/s41467-020-14321-0. Nat Commun. 2020. PMID: 31969570 Free PMC article.

10

Pharmacological characterization of a novel negative allosteric modulator of NMDA receptors, UBP792.

Sapkota K, Burnell ES, Irvine MW, Fang G, Gawande DY, Dravid SM, Jane DE, Monaghan DT. Sapkota K, et al. Among authors: monaghan dt. Neuropharmacology. 2021 Dec 15;201:108818. doi: 10.1016/j.neuropharm.2021.108818. Epub 2021 Oct 2. Neuropharmacology. 2021. PMID: 34610288

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results